- Home
- FEBO vs QNRX Comparison
FEBO vs QNRX Comparison
Compare FEBO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | QNRX |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 9.2M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FEBO | QNRX |
|---|---|---|
| Price | $0.70 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.71 |
| AVG Volume (30 Days) | 12.5K | ★ 39.2K |
| Earning Date | 05-15-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $3.25 |
| 52 Week High | $1.46 | $23.50 |
Technical Indicators
Market Signals| Indicator | FEBO | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 27.72 |
| Support Level | $0.65 | $3.25 |
| Resistance Level | $0.78 | $4.50 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 50.70 | 6.48 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.